Sheena Jonathan, co-founder and director of Natera, Inc. (NASDAQ:NTRA), sold company common stock totaling approximately $410,825 on July 15, 2026. The transactions involved a total of 1,500 shares, executed through various sales at prices ranging from $273.0088 to $276.38 per share.
The sales were made indirectly through the Caraluna 1 Trust and Caraluna 2 Trust, for which Ms. Jonathan disclaims beneficial ownership. These transactions were carried out under a Rule 10b5-1 trading plan, which was adopted by Ms. Jonathan on June 7, 2024.The timing of the sale is notable as Natera shares are trading near their 52-week high of $288.04, with the stock delivering a 95% return over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, placing it among companies on the most overvalued list. Investors can access detailed valuation metrics and 10 additional InvestingPro Tips, plus a comprehensive Pro Research Report covering NTRA’s financial health and growth prospects.
Following these sales, Ms. Jonathan directly holds 246,202 shares of Natera common stock. The Caraluna 1 Trust now holds 18,032 shares, and the Caraluna 2 Trust also holds 18,032 shares.
In other recent news, Natera Inc. announced that its Signatera test has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR) as a Class C device. This certification covers the entire Signatera platform, including its assay and specimen collection kit. Additionally, Natera’s Signatera test received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency, marking it as the first PMDA-approved molecular residual disease test in Japan for colorectal cancer in the adjuvant setting. The company plans to commercially launch the test in Japan by the end of 2026, contingent on final pricing.
In partnership news, Natera has teamed up with Aveta Biomics for a Phase 3 clinical trial focused on head and neck squamous cell carcinoma, utilizing the Signatera test to assess molecular residual disease and treatment response. Furthermore, a study published in JAMA Oncology highlighted the predictive capabilities of the Signatera test for chemotherapy benefits in liver cancer patients. This study involved 298 patients with colorectal liver metastases and was part of the GALAXY trial.
On the financial front, Bernstein SocGen Group resumed coverage of Natera with an outperform rating, citing the company’s potential for increased volumes and reimbursement in minimal residual disease testing. Japan is expected to play a significant role as a volume driver, with anticipated PMDA reimbursement in the second quarter and a commercial launch before year-end.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
investment News
